ARTICLE
19 December 2022

Life Sciences: Extension To The Deadline For Implementation Of The MDR

M
Matheson
Contributor
Established in 1825 in Dublin, Ireland and with offices in Cork, London, New York, Palo Alto and San Francisco, more than 700 people work across Matheson’s six offices, including 96 partners and tax principals and over 470 legal and tax professionals. Matheson services the legal needs of internationally focused companies and financial institutions doing business in and from Ireland. Our clients include over half of the world’s 50 largest banks, 6 of the world’s 10 largest asset managers, 7 of the top 10 global technology brands and we have advised the majority of the Fortune 100.
An updated EU regulatory framework for medical devices was adopted in 2017 in order to address the shortcomings of the previous regime which has been in place for over 25 years as well...
Ireland Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

An updated EU regulatory framework for medical devices was adopted in 2017 in order to address the shortcomings of the previous regime which has been in place for over 25 years as well as to capture the developments in medical technologies that has taken place in that time. The new framework consists of two new EU regulations, the Medical Devices Regulation 2017/745 ("MDR") and In Vitro Diagnostic Regulation 2017/746 ("IVDR"), which were adopted in April 2017.

The Regulations have a staggered transitional period which originally anticipated full application of the MDR from May 2020 and full application of the IVDR from May 2022. However, as we discuss in our previous Insight, in the context of the unprecedented challenges posed by the outbreak of the Covid-19 pandemic, it was decided to extend the relevant periods for implementation of this new regime.

The updated timeline envisaged that by 26 May 2024 all devices placed on the market must be in compliance with the MDR. However, as this deadline draws nearer, medical and industry associations have expressed fears that the more stringent regulatory regime, which requires all devices to be re-certified, would lead to delays in approval of vital medical devices.

At a meeting of the EPSCO Council on 9 December 2022, the EU Health Commissioner Stella Kyriakides further cited the impact of Russia's war against Ukraine on the availability of raw materials and delays in the designation of notified bodies, which are responsible for the assessment and approval of medical devices, as strains on market readiness for full implementation of the MDR. In order to mitigate the risk of EU-wide shortages in supply of life-saving medical equipment, Commissioner Kyriakides proposed amending the MDR to further extend to the deadline for compliance with its provisions (the "Proposal").

The Proposal will introduce staggered deadlines based on classification of devices according to their risk, extending to 2027 in respect of high risk devices and 2028 in respect of medium and low risk devices. Importantly, it is proposed that qualification for the extension would be conditional on satisfying certain conditions as to safety. Further, in order to prevent the discarding of safe medical devices, it is proposed to abolish the deadline of 26 May 2025 for the "sell off" of products lawfully placed on the market under the previous regulatory regime.

The Proposal will be formally tabled before the European Parliament and the Council of the EU in January 2023. Its approval would go some way to alleviating the significant challenges to manufactures of medical devices in seeking to adapt to the new requirements under the MDR.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
19 December 2022

Life Sciences: Extension To The Deadline For Implementation Of The MDR

Ireland Food, Drugs, Healthcare, Life Sciences
Contributor
Established in 1825 in Dublin, Ireland and with offices in Cork, London, New York, Palo Alto and San Francisco, more than 700 people work across Matheson’s six offices, including 96 partners and tax principals and over 470 legal and tax professionals. Matheson services the legal needs of internationally focused companies and financial institutions doing business in and from Ireland. Our clients include over half of the world’s 50 largest banks, 6 of the world’s 10 largest asset managers, 7 of the top 10 global technology brands and we have advised the majority of the Fortune 100.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More